Please login to the form below

Not currently logged in
Email:
Password:

Dutch biotech Mucosis promotes Thomas Johnston to CEO

He succeeds Govert Schouten who leaves to found an internet start-up

Dutch biotech Mucosis Thomas JohnstonThomas Johnston has been promoted to CEO of Mucosis to take over from Govert Schouten, who is leaving the Dutch clinical-stage biotech to found an internet start-up.

Johnston joined Mucosis last May as chief business officer from the clinical biopharmaceutical company Novavax, where he served as vice president of strategy.

Prior to that he served as an executive-level strategic consultant in a number of industries including biotech, and held various senior-level positions with companies such as Comcast, Microsoft, and Schlumberger.

John Lambert, chairman of the Mucosis board of directors, said: "Tom has more than 15 years of leadership experience in the biotech and other industries and has been an invaluable member of our executive management team.

“Given Tom's substantial commercial experience and familiarity with the Company, we are confident he is the right person to lead Mucosis as we execute our strategy and further advance the development and commercialisation of the Mimopath platform including our RSV vaccine candidate."

During the last 12 months Mucosis has completed a clinical proof of concept study in human influenza for Mimopath and advanced respiratory syncytial virus (RSV) candidate SynGEM into pre-clinical studies.

19th September 2012

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Windrose Consulting Group

Windrose Consulting Group helps life science companies maximize the commercial value of their products and bring new innovations to market...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics